Qing Sarah Yuan
Directeur Technique/Scientifique/R&D chez SIGILON THERAPEUTICS, INC.
Profil
Qing Sarah Yuan is currently the Chief Technical Operations Officer at Sigilon Therapeutics, Inc. Prior to this, she worked as the Head-Technical Development at Bioverativ, Inc. from 2017 to 2019.
She also held the position of Vice President-Process & Analytical Development at 2seventy Bio, Inc. Dr. Yuan holds a doctorate degree from the University of Wisconsin and an undergraduate degree from the University of California, Berkeley.
Postes actifs de Qing Sarah Yuan
| Sociétés | Poste | Début |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 07/03/2022 |
Anciens postes connus de Qing Sarah Yuan
| Sociétés | Poste | Fin |
|---|---|---|
| BIOVERATIV INC | Corporate Officer/Principal | 01/01/2019 |
| 2SEVENTY BIO, INC. | Corporate Officer/Principal | - |
Formation de Qing Sarah Yuan
| University of Wisconsin | Doctorate Degree |
| University of California, Berkeley | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SIGILON THERAPEUTICS, INC. | Health Technology |
| 2SEVENTY BIO, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |